The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | The application of JAK inhibitors in the treatment of polycythemia vera and myelofibrosis
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses janus kinase (JAK) inhibitors at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. There is only one drug approved, at present, for the treatment of polycythemia vera (PV) and myelofibrosis (MF) – ruxolitinib a JAK1/JAK2 inhibitor. Dr Ali-Ali also discusses pacritinib, a JAK1 inhibitor and momelotinib, a JAK1 and JAK2 inhibitor. Fedratinib is a JAK2 inhibitor however, development of fedratinib has been halted due to safety concerns as some patients have developed Wernicke’s encephalopathy.
